<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2018-02-23" updated="2019-12-02">
  <drugbank-id primary="true">DB13995</drugbank-id>
  <drugbank-id>DBSALT001314</drugbank-id>
  <name>Ferric pyrophosphate citrate</name>
  <description>Ferric pyrophosphate citrate is a soluble iron replacement product. Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma. The ferric ion is strongly complexed by pyrophosphate and citrate.[A31979] FPC is categorized in Japan as a second class OTC drug.[L1420] This category is given to drugs with ingredients that in rare cases may cause health problems requiring hospitalization or worst.[L1419] It is also FDA approved since 2015.[FDA label]</description>
  <cas-number>1802359-96-1</cas-number>
  <unii>UBY79OCO9G</unii>
  <average-mass>1321.571</average-mass>
  <monoisotopic-mass>1321.556531</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A31979</ref-id>
        <pubmed-id>10231452</pubmed-id>
        <citation>Gupta A, Amin NB, Besarab A, Vogel SE, Divine GW, Yee J, Anandan JV: Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int. 1999 May;55(5):1891-8. doi: 10.1046/j.1523-1755.1999.00436.x.</citation>
      </article>
      <article>
        <ref-id>A31984</ref-id>
        <pubmed-id>22942439</pubmed-id>
        <citation>Naigamwalla DZ, Webb JA, Giger U: Iron deficiency anemia. Can Vet J. 2012 Mar;53(3):250-6.</citation>
      </article>
      <article>
        <ref-id>A31991</ref-id>
        <pubmed-id>14748943</pubmed-id>
        <citation>Fidler MC, Walczyk T, Davidsson L, Zeder C, Sakaguchi N, Juneja LR, Hurrell RF: A micronised, dispersible ferric pyrophosphate with high relative bioavailability in man. Br J Nutr. 2004 Jan;91(1):107-12.</citation>
      </article>
      <article>
        <ref-id>A31994</ref-id>
        <pubmed-id>27557937</pubmed-id>
        <citation>Pratt RD, Swinkels DW, Ikizler TA, Gupta A: Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers. J Clin Pharmacol. 2017 Mar;57(3):312-320. doi: 10.1002/jcph.819. Epub 2016 Oct 3.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T118</ref-id>
        <isbn/>
        <citation>Underwood E. (1977). Trace elements in human and animal nutrition (4th ed.). Academic press.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L1420</ref-id>
        <title>KEGG</title>
        <url>http://www.genome.jp/dbget-bin/www_bget?D04946</url>
      </link>
      <link>
        <ref-id>L1419</ref-id>
        <title>Nippon</title>
        <url>https://www.nippon.com/en/currents/d00106/</url>
      </link>
      <link>
        <ref-id>L1423</ref-id>
        <title>FDA Reports</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206317orig1s000medr.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Ferric pyrophosphate citrate is indicated for the treatment of iron loss or iron deficiency to maintain hemoglobin and to reduce the prescribed dose of erythropoiesis-stimulating agent (ESA) required to maintain desired hemoglobin levels.[L1423] &#13;
&#13;
Iron deficiency appears when the dietary intake does not meet the body's requirement or when there is chronic external blood loss. During acute blood loss, body iron stores are sufficient for accelerated erythropoiesis and restoration of iron homeostasis. But when the altered homeostasis remains for weeks to months then some supplement is needed. Some causes of iron deficiency include ectoparasitism, endoparasitism, hematuria, epistaxis, hemorrhagic skin, coagulopathy, thrombocytopenia, thrombocytopathia and gastrointestinal hemorrhage.[A31984]</indication>
  <pharmacodynamics>Iron supplementation typically results in increases in serum iron, transferrin-bound iron, and iron-stored in the form of ferritin in hepatocytes and macrophages. The available iron is usually used in bone marrow for the synthesis of hemoglobin.[L1423]</pharmacodynamics>
  <mechanism-of-action>The usage of ferric pyrophosphate is based on the strong complex formation between these two species. Besides, the capacity of pyrophosphate to trigger iron removal from transferrin, enhance iron transfer from transferrin to ferritin and promote iron exchange between transferrin molecules. These properties make it a very suitable compound for parenteral administration, iron delivery into circulation and incorporation into hemoglobin.[A31979]</mechanism-of-action>
  <toxicity>Ferric pyrophosphate was showed to be clastogenic in the in vitro chromosomal aberration assay in presence of metabolic activation. It was not showed to have mutagenic or fertility effects and its carcinogenic potential have not been studied yet.[FDA label]</toxicity>
  <metabolism>Metabolism of ferric pyrophosphate resembles physiological processing of iron delivered into circulation after absorption by the gut. This is suggested due to the direct ability to trigger iron transfer to transferrin, between transferrin molecules and between transferrin and ferritin without the need of prior metabolism by the reticuloendothelial system.[A31979]</metabolism>
  <absorption>The results of the present studies show that ferric pyrophosphate is as well absorbed in adults. The absorption of iron depends upon the route of entry. Ferric pyrophosphate has a very high bioavailability of 83-94%.[A31991] The AUC and Cmax have a dose-dependent pharmacokinetic response, being of 675-1840 mcg.h/dL and 113-261 mcg/dL respectively when given in a dose from 2.5 to 10 mg. The time to reach maximum dose is approximate 4.5 hours.[A31994]</absorption>
  <half-life>The half-life of ferric pyrophosphate is 1.48 hours.[A31994]</half-life>
  <protein-binding>The main action site of ferric pyrophosphate is in the serum and thus it is highly bound to its targets such as ferritin and hemoglobin.[A31994]</protein-binding>
  <route-of-elimination>After metabolism as endogenous iron, the excretion of ferric pyrophosphate follows the same pattern. In the body, iron is retained and in the absence of bleeding the excretion is very small. Most of the iron is absorbed in the gut and does not reach the feces. The excretion of iron can be done in urine, feces, sweat, hair, and nails.[T118]</route-of-elimination>
  <volume-of-distribution>The apparent volume of distribution of ferric pyrophosphate after 4 hours of intravenous administration ranged from 0.765 to 0.859 L.[FDA label]</volume-of-distribution>
  <clearance>The mean clearance rate of ferric pyrophosphate can range between 0.406 to 0.556 L/hour.[A31994]</clearance>
  <salts/>
  <synonyms>
    <synonym language="english" coder="usan">Ferric pyrophosphate citrate</synonym>
    <synonym language="english" coder="">FPC</synonym>
    <synonym language="english" coder="">SFP</synonym>
    <synonym language="english" coder="">Tetraferric nonahydrogen citrate pyrophosphate</synonym>
    <synonym language="english" coder="">Triferic</synonym>
  </synonyms>
  <products>
    <product>
      <name>Triferic</name>
      <labeller>Ropack Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>64811-315</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-11-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>272 mg/272mg</strength>
      <route>Parenteral</route>
      <fda-application-number>NDA208551</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triferic</name>
      <labeller>Rockwell Medical, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>57278-316</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>272 mg/50mL</strength>
      <route>Hemodialysis; Intravenous</route>
      <fda-application-number>NDA206317</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triferic</name>
      <labeller>Rockwell Medical, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>57278-314</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>5.44 mg/1mL</strength>
      <route>Hemodialysis</route>
      <fda-application-number>NDA206317</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Triferic</name>
      <labeller>Rockwell Medical, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>57278-315</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>272 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA208551</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Incremin</name>
      <company>Pfizer</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Triferic</name>
      <ingredients>Ferric pyrophosphate citrate</ingredients>
    </mixture>
    <mixture>
      <name>Triferic</name>
      <ingredients>Ferric pyrophosphate citrate</ingredients>
    </mixture>
    <mixture>
      <name>Triferic</name>
      <ingredients>Ferric pyrophosphate citrate</ingredients>
    </mixture>
    <mixture>
      <name>Triferic</name>
      <ingredients>Ferric pyrophosphate citrate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Parenteral Iron Replacement</category>
      <mesh-id/>
    </category>
    <category>
      <category>Peptide Hydrolases</category>
      <mesh-id>D010447</mesh-id>
    </category>
    <category>
      <category>Phosphate Binder</category>
      <mesh-id/>
    </category>
    <category>
      <category>Phosphate salts</category>
      <mesh-id>D010710</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder</form>
      <route>Intravenous</route>
      <strength>272 mg/1</strength>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route>Parenteral</route>
      <strength>272 mg/272mg</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Hemodialysis</route>
      <strength>5.44 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Hemodialysis; Intravenous</route>
      <strength>272 mg/50mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB13995.pdf?1519666540</fda-label>
  <patents>
    <patent>
      <number>6779468</number>
      <country>United States</country>
      <approved>2004-08-24</approved>
      <expires>2016-12-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7816404</number>
      <country>United States</country>
      <approved>2010-10-19</approved>
      <expires>2029-04-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6689275</number>
      <country>United States</country>
      <approved>2004-02-10</approved>
      <expires>2016-12-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7857977</number>
      <country>United States</country>
      <approved>2010-12-28</approved>
      <expires>2027-09-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic acid</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05488</drugbank-id>
      <name>Technetium Tc-99m ciprofloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11404</drugbank-id>
      <name>Enrofloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11443</drugbank-id>
      <name>Orbifloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11491</drugbank-id>
      <name>Sarafloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11511</drugbank-id>
      <name>Difloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13261</drugbank-id>
      <name>Sitafloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13772</drugbank-id>
      <name>Rufloxacin</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13823</drugbank-id>
      <name>Pipemidic acid</name>
      <description>Ferric pyrophosphate citrate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01370</drugbank-id>
      <name>Aluminium</name>
      <description>Aluminium can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>Magnesium oxide can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>Aluminum hydroxide can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>Magnesium hydroxide can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>Magnesium trisilicate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>Magnesium carbonate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>Magnesium silicate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13280</drugbank-id>
      <name>Aluminium acetoacetate</name>
      <description>Aluminium acetoacetate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>Magnesium peroxide can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13626</drugbank-id>
      <name>Aluminium glycinate</name>
      <description>Aluminium glycinate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>Nitroprusside can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00893</drugbank-id>
      <name>Iron Dextran</name>
      <description>Iron Dextran can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01592</drugbank-id>
      <name>Iron</name>
      <description>Iron can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06215</drugbank-id>
      <name>Ferumoxytol</name>
      <description>Ferumoxytol can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06783</drugbank-id>
      <name>Prussian blue</name>
      <description>Prussian blue can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08917</drugbank-id>
      <name>Ferric carboxymaltose</name>
      <description>Ferric carboxymaltose can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09146</drugbank-id>
      <name>Iron sucrose</name>
      <description>Iron sucrose can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09147</drugbank-id>
      <name>Ferric pyrophosphate</name>
      <description>Ferric pyrophosphate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09501</drugbank-id>
      <name>Ferric ammonium citrate</name>
      <description>Ferric ammonium citrate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09507</drugbank-id>
      <name>Ferumoxsil</name>
      <description>Ferumoxsil can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09508</drugbank-id>
      <name>Ferumoxides</name>
      <description>Ferumoxides can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11171</drugbank-id>
      <name>Ferric sulfate</name>
      <description>Ferric sulfate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11210</drugbank-id>
      <name>Ferrous bisglycinate</name>
      <description>Ferrous bisglycinate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11417</drugbank-id>
      <name>Gleptoferron</name>
      <description>Gleptoferron can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11576</drugbank-id>
      <name>Ferric oxide</name>
      <description>Ferric oxide can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12208</drugbank-id>
      <name>Iron isomaltoside 1000</name>
      <description>Iron isomaltoside 1000 can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12821</drugbank-id>
      <name>Perflubutane</name>
      <description>Perflubutane can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13257</drugbank-id>
      <name>Ferrous sulfate anhydrous</name>
      <description>Ferrous sulfate anhydrous can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13381</drugbank-id>
      <name>Sodium feredetate</name>
      <description>Sodium feredetate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13423</drugbank-id>
      <name>Ferric hydroxide</name>
      <description>Ferric hydroxide can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13569</drugbank-id>
      <name>Ferrous chloride</name>
      <description>Ferrous chloride can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13949</drugbank-id>
      <name>Ferric cation</name>
      <description>Ferric cation can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14488</drugbank-id>
      <name>Ferrous gluconate</name>
      <description>Ferrous gluconate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14489</drugbank-id>
      <name>Ferrous succinate</name>
      <description>Ferrous succinate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14491</drugbank-id>
      <name>Ferrous fumarate</name>
      <description>Ferrous fumarate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14520</drugbank-id>
      <name>Tetraferric tricitrate decahydrate</name>
      <description>Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14695</drugbank-id>
      <name>Ferric oxyhydroxide</name>
      <description>Ferric oxyhydroxide can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.72</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>7.60e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>tetrairon(3+) bis((phosphonooxy)phosphonic acid) tris(2-hydroxypropane-1,2,3-tricarboxylate) (hydrogen phosphonooxy)phosphonate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>tetrairon(3+) bis(pyrophosphoric acid) tricitrate hydrogen phosphonooxyphosphonate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>1321.571</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>1321.556531</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[Fe+3].[Fe+3].[Fe+3].[Fe+3].OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(O)=O.OP([O-])(=O)OP([O-])([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C18H24Fe4O42P6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/3C6H8O7.4Fe.3H4O7P2/c3*7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;3*1-8(2,3)7-9(4,5)6/h3*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;;3*(H2,1,2,3)(H2,4,5,6)/q;;;4*+3;;;/p-12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>SXAWSYZURCZSDX-UHFFFAOYSA-B</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>140.62</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>68.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>14.23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>21</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>3.05</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-4.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Soluble </value>
      <source>FDA label</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>309.6ºC at 760 mmHg</value>
      <source>'MSDS-online'</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>34994433</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL3833317</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000085</id>
      <name>Ferritin light chain</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A31979</ref-id>
            <pubmed-id>10231452</pubmed-id>
            <citation>Gupta A, Amin NB, Besarab A, Vogel SE, Divine GW, Yee J, Anandan JV: Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int. 1999 May;55(5):1891-8. doi: 10.1046/j.1523-1755.1999.00436.x.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P02792" source="Swiss-Prot">
        <name>Ferritin light chain</name>
        <general-function>Iron ion binding</general-function>
        <specific-function>Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney (By similarity).</specific-function>
        <gene-name>FTL</gene-name>
        <locus>19q13.3-q13.4</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.59</theoretical-pi>
        <molecular-weight>20019.49</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3999</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>FTL</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M11147</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>182514</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02792</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FRIL_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Ferritin L subunit</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036948|Ferritin light chain
MSSQIRQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKR
EGYERLLKMQNQRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSA
RTDPHLCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFERLTLKHD</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016009|Ferritin light chain (FTL)
ATGAGCTCCCAGATTCGTCAGAATTATTCCACCGACGTGGAGGCAGCCGTCAACAGCCTG
GTCAATTTGTACCTGCAGGCCTCCTACACCTACCTCTCTCTGGGCTTCTATTTCGACCGC
GATGATGTGGCTCTGGAAGGCGTGAGCCACTTCTTCCGCGAATTGGCCGAGGAGAAGCGC
GAGGGCTACGAGCGTCTCCTGAAGATGCAAAACCAGCGTGGCGGCCGCGCTCTCTTCCAG
GACATCAAGAAGCCAGCTGAAGATGAGTGGGGTAAAACCCCAGACGCCATGAAAGCTGCC
ATGGCCCTGGAGAAAAAGCTGAACCAGGCCCTTTTGGATCTTCATGCCCTGGGTTCTGCC
CGCACGGACCCCCATCTCTGTGACTTCCTGGAGACTCACTTCCTAGATGAGGAAGTGAAG
CTTATCAAGAAGATGGGTGACCACCTGACCAACCTCCACAGGCTGGGTGGCCCGGAGGCT
GGGCTGGGCGAGTATCTCTTCGAAAGGCTCACTCTCAAGCACGACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00210</identifier>
            <name>Ferritin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular ferritin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ferric iron binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>iron ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-Golgi vesicle-mediated transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000399</id>
      <name>Ferritin heavy chain</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A31979</ref-id>
            <pubmed-id>10231452</pubmed-id>
            <citation>Gupta A, Amin NB, Besarab A, Vogel SE, Divine GW, Yee J, Anandan JV: Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int. 1999 May;55(5):1891-8. doi: 10.1046/j.1523-1755.1999.00436.x.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P02794" source="Swiss-Prot">
        <name>Ferritin heavy chain</name>
        <general-function>Iron ion binding</general-function>
        <specific-function>Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney (By similarity).</specific-function>
        <gene-name>FTH1</gene-name>
        <locus>11q13</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.29</theoretical-pi>
        <molecular-weight>21225.47</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3976</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>FTH1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X00318</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>28435</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02794</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FRIH_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.16.3.1</synonym>
          <synonym>Cell proliferation-inducing gene 15 protein</synonym>
          <synonym>Ferritin H subunit</synonym>
          <synonym>FTH</synonym>
          <synonym>FTHL6</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037008|Ferritin heavy chain
MTTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQS
HEEREHAEKLMKLQNQRGGRIFLQDIKKPDCDDWESGLNAMECALHLEKNVNQSLLELHK
LATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSD
NES</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016083|Ferritin heavy chain (FTH1)
ATGACGACCGCGTCCACCTCGCAGGTGCGCCAGAACTACCACCAGGACTCAGAGGCCGCC
ATCAACCGCCAGATCAACCTGGAGCTCTACGCCTCCTACGTTTACCTGTCCATGTCTTAC
TACTTTGACCGCGATGATGTGGCTTTGAAGAACTTTGCCAAATACTTTCTTCACCAATCT
CATGAGGAGAGGGAACATGCTGAGAAACTGATGAAGCTGCAGAACCAACGAGGTGGCCGA
ATCTTCCTTCAGGATATCAAGAAACCAGACTGTGATGACTGGGAGAGCGGGCTGAATGCA
ATGGAGTGTGCATTACATTTGGAAAAAAATGTGAATCAGTCACTACTGGAACTGCACAAA
CTGGCCACTGACAAAAATGACCCCCATTTGTGTGACTTCATTGAGACACATTACCTGAAT
GAGCAGGTGAAAGCCATCAAAGAATTGGGTGACCACGTGACCAACTTGCGCAAGATGGGA
GCGCCCGAATCTGGCTTGGCGGAATATCTCTTTGACAAGCACACCCTGGGAGACAGTGAT
AATGAAAGCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00210</identifier>
            <name>Ferritin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular ferritin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ferric iron binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ferroxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular iron ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular sequestering of iron ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>iron ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>membrane organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of fibroblast proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-Golgi vesicle-mediated transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0000130</id>
      <name>Hemoglobin subunit alpha</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A31979</ref-id>
            <pubmed-id>10231452</pubmed-id>
            <citation>Gupta A, Amin NB, Besarab A, Vogel SE, Divine GW, Yee J, Anandan JV: Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int. 1999 May;55(5):1891-8. doi: 10.1046/j.1523-1755.1999.00436.x.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P69905" source="Swiss-Prot">
        <name>Hemoglobin subunit alpha</name>
        <general-function>Oxygen transporter activity</general-function>
        <specific-function>Involved in oxygen transport from the lung to the various peripheral tissues.</specific-function>
        <gene-name>HBA1</gene-name>
        <locus>16p13.3</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.09</theoretical-pi>
        <molecular-weight>15257.405</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4823</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HBA1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J00153</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>386764</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P69905</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>HBA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Alpha-globin</synonym>
          <synonym>Hemoglobin alpha chain</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036956|Hemoglobin subunit alpha
MVLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTKTYFPHFDLSHGSAQVKGHG
KKVADALTNAVAHVDDMPNALSALSDLHAHKLRVDPVNFKLLSHCLLVTLAAHLPAEFTP
AVHASLDKFLASVSTVLTSKYR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010173|Hemoglobin subunit alpha (HBA1)
ATGGTGCTGTCTCCTGCCGACAAGACCAACGTCAAGGCCGCCTGGGGTAAGGTCGGCGCG
CACGCTGGCGAGTATGGTGCGGAGGCCCTGGAGAGGATGTTCCTGTCCTTCCCCACCACC
AAGACCTACTTCCCGCACTTCGACCTGAGCCACGGCTCTGCCCAGGTTAAGGGCCACGGC
AAGAAGGTGGCCGACGCGCTGACCAACGCCGTGGCGCACGTGGACGACATGCCCAACGCG
CTGTCCGCCCTGAGCGACCTGCACGCGCACAAGCTTCGGGTGGACCCGGTCAACTTCAAG
CTCCTAAGCCACTGCCTGCTGGTGACCCTGGCCGCCCACCTCCCCGCCGAGTTCACCCCT
GCGGTGCACGCCTCCCTGGACAAGTTCCTGGCTTCTGTGAGCACCGTGCTGACCTCCAAA
TACCGTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00042</identifier>
            <name>Globin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosolic small ribosomal subunit</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>haptoglobin-hemoglobin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>hemoglobin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bicarbonate transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxygen transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hydrogen peroxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0000629</id>
      <name>Hemoglobin subunit beta</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A31979</ref-id>
            <pubmed-id>10231452</pubmed-id>
            <citation>Gupta A, Amin NB, Besarab A, Vogel SE, Divine GW, Yee J, Anandan JV: Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int. 1999 May;55(5):1891-8. doi: 10.1046/j.1523-1755.1999.00436.x.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P68871" source="Swiss-Prot">
        <name>Hemoglobin subunit beta</name>
        <general-function>Oxygen transporter activity</general-function>
        <specific-function>Involved in oxygen transport from the lung to the various peripheral tissues.LVV-hemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure.Spinorphin: functions as an endogenous inhibitor of enkephalin-degrading enzymes such as DPP3, and as a selective antagonist of the P2RX3 receptor which is involved in pain signaling, these properties implicate it as a regulator of pain and inflammation.</specific-function>
        <gene-name>HBB</gene-name>
        <locus>11p15.5</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.32</theoretical-pi>
        <molecular-weight>15998.34</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4827</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HBB</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U01317</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>455997</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P68871</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>HBB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Beta-globin</synonym>
          <synonym>Hemoglobin beta chain</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010439|Hemoglobin subunit beta
MVHLTPEEKSAVTALWGKVNVDEVGGEALGRLLVVYPWTQRFFESFGDLSTPDAVMGNPK
VKAHGKKVLGAFSDGLAHLDNLKGTFATLSELHCDKLHVDPENFRLLGNVLVCVLAHHFG
KEFTPPVQAAYQKVVAGVANALAHKYH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010440|Hemoglobin subunit beta (HBB)
ATGGTGCATCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAAC
GTGGATGAAGTTGGTGGTGAGGCCCTGGGCAGGCTGCTGGTGGTCTACCCTTGGACCCAG
AGGTTCTTTGAGTCCTTTGGGGATCTGTCCACTCCTGATGCTGTTATGGGCAACCCTAAG
GTGAAGGCTCATGGCAAGAAAGTGCTCGGTGCCTTTAGTGATGGCCTGGCTCACCTGGAC
AACCTCAAGGGCACCTTTGCCACACTGAGTGAGCTGCACTGTGACAAGCTGCACGTGGAT
CCTGAGAACTTCAGGCTCCTGGGCAACGTGCTGGTCTGTGTGCTGGCCCATCACTTTGGC
AAAGAATTCACCCCACCAGTGCAGGCTGCCTATCAGAAAGTGGTGGCTGGTGTGGCTAAT
GCCCTGGCCCACAAGTATCACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00042</identifier>
            <name>Globin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>haptoglobin-hemoglobin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>hemoglobin complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>hemoglobin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bicarbonate transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nitric oxide transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxygen transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet aggregation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood vessel size</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>renal absorption</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hydrogen peroxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>